5th Circuit Bans Mifepristone Mail Distribution; Drugmakers Rush to Supreme Court
The Fifth Circuit voided FDA’s 2021 mail-dispensing rule for mifepristone, banning telehealth prescribing nationwide. The Supreme Court issued an emergency stay May 14.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed